⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 17, 2026Journal of Medical EconomicsOpen Access

Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland

Muloongo Simuzingili Andrea Favre-Bulle Thomas Mutschler Zinan Yi Eleana Tsoumani Kwame Owusu‐Edusei

View Full Paper

Ask AI

Bookmark

Share

Key Points

This analysis evaluates the health and economic benefits of PCV21 compared to PCV20 in older adults.
Conducted cost-effectiveness analysis
Compared economic benefits of PCV21 and PCV20
Assessed the impact of price premiums on cost-effectiveness
PCV21 demonstrates greater health benefits than PCV20
Cost-effectiveness remains favorable across various price premiums
Overall economic analysis supports PCV21 over PCV20 for older adults

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Analysis shows PCV21 provides greater health benefits in adults aged 65+, indicating cost-effectiveness.

Abstract

PCV21 provides greater health and economic benefits than PCV20 and is cost-effective over a range of price premiums.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Simuzingili et al. (2026) studied this question.

synapsesocial.com/papers/6997fa6dad1d9b11b3453a90 https://doi.org/10.1080/13696998.2026.2622857

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland2024 · 1 citations
2A cost-effectiveness analysis of 21-valent and 20-valent pneumococcal conjugate vaccines in adults aged 65 years in ItalyOriginal Research · 2026
3The incremental net monetary benefit of higher-valent pneumococcal conjugate vaccines for adults: a systematic review and meta-analysis of economic evaluations2025 · 2 citations
4Cost effectiveness and public health impact of PCV20 among adults in FranceOriginal Research · 2026
5Simplifying Adult Pneumococcal Vaccination in India: A Cost-Effectiveness Analysis of the 20-Valent Conjugate VaccineOriginal Research · 2026
6An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population2024 · 19 citations
7Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis2024 · 39 citations
8Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years in SingaporeCost-Effectiveness Analysis · 2025 · 1 citations
9Comparison of 1-year costs of commercially insured patients with severe aortic stenosis undergoing surgical vs. transcatheter aortic valve replacementJournal of Medical Economics · 2026
10Evaluating the cost-effectiveness of enhanced cardiovascular-renal-metabolic (CVRM) screening in UK, France, Germany and Australia: a microsimulation-based enhanced CVRM screening analysisJournal of Medical Economics · 2026

More from Journal of Medical Economics

More from Merck & Co., Inc., Rahway, NJ, USA (United States)

More from MSD (Switzerland)